Evaluating the Evolving Real-World Adverse Events of GLP-1RAs Using FDA Adverse Event Reporting System (FAERS)

Wiley Online Library·Mar 9

✦ NabkaNews BriefAuto-summarized from multiple outlets · verify with the source

Research is being conducted on the real-world adverse events associated with GLP-1 receptor agonists. The safety and efficacy of these drugs are being evaluated and compared, with some studies focusing on their use in treating diabetes, obesity, and other diseases. The risks associated with GLP-1 drugs are being scrutinized, but the extent of these risks is not clear.

Full coverage

Comprehensive evaluation of GLP-1 receptor agonists: an umbrella review of clinical outcomes across multiple diseases

Nature·Jan 7

Small-Molecule Oral Versus Injectable Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists: Comparative Efficacy, Safety, and Future Clinical Perspectives

Cureus·Apr 16

GLP-1 Drugs Under Scrutiny: How Real Are the Risks?

Medscape·Apr 6

SGLT2 vs GLP-1: Individualizing Diabetes, Cardiovascular, and Renal Outcomes

Clinical Advisor·May 15

GLP-1 agonists and changes in body mass and composition in adults with overweight or obesity with or without type 2 diabetes mellitus: a systematic review and meta-analysis | International Journal of Obesity

Nature·Apr 25

GLP-1 receptor agonists: exploration of transformation from metabolic regulation to multi-organ therapy

Frontiers·Aug 28

GLP-1 Receptor Agonists in Metabolic Dysfunction-Associated Steatotic Liver Disease: Bridging Hepatic and Cardiovascular Outcomes

Wiley Online Library·Mar 24

GLP-1 drugs – how real are the risks?

Juta MedicalBrief·Apr 22

View original report at Wiley Online Library ↗

Fetching the latest headlines…